Advancing the potential of nanoparticles for cancer detection and precision therapeutics DOI

Muhammad Naeem Kiani,

Hamza Khaliq,

Muhammad Abubakar

et al.

Medical Oncology, Journal Year: 2025, Volume and Issue: 42(7)

Published: June 4, 2025

Language: Английский

Molecular docking technology drives multidimensional applications of microbial natural products DOI

Chan Zhang,

Qingjie Sun,

Arzugul Ablimit

et al.

Journal of Molecular Structure, Journal Year: 2025, Volume and Issue: unknown, P. 142044 - 142044

Published: March 1, 2025

Language: Английский

Citations

0
The 3C (Cell Culture, Computer Simulation, Clinical Trial) Solution for Optimizing the 3R (Replace, Reduction, Refine) Framework during Preclinical Research Involving Laboratory Animals DOI
Sounak Roy,

Mubeena Parveen,

Asis Bala

et al.

ACS Pharmacology & Translational Science, Journal Year: 2025, Volume and Issue: unknown

Published: April 9, 2025

Preclinical research has traditionally utilized laboratory animals to elucidate the safety, tolerability, pharmacokinetics, and pharmacodynamics of new chemical entities prior human trials. The use animal models been pivotal in advancing scientific knowledge medical breakthroughs, contributing significantly our understanding complex biological processes diseases. However, many promising treatments that have demonstrated efficacy studies failed translate subjects during clinical Consequently, testing faces ethical concerns criticism regarding its predictive reliability for responses. This led development 3R principles (Replacement, Reduction, Refinement), introduced 1959, advocating alternative methods improved welfare research. Furthermore, regulatory frameworks recent legislation, such as 2022 FDA Modernisation Act, emphasize modern alternatives traditional testing. Emerging approaches, known 3Cs-cell culture, computer simulation, phase 0 trials-offer nonanimal solutions could accelerate drug address concerns, potentially rendering preclinical more humane efficient.

Language: Английский

Citations

0
Acridine-Based Chalcone 1C and ABC Transporters DOI Open Access

Ondrej Franko,

Martina Čižmáriková, Martin Kello

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(9), P. 4138 - 4138

Published: April 27, 2025

Chalcones, potential anticancer agents, have shown promise in the suppression of multidrug resistance due to inhibition drug efflux driven by certain adenosine triphosphate (ATP)-binding cassette (ABC) transporters. The gene and protein expression chosen ABC transporters (multidrug 1, ABCB1; resistance-associated ABCC1; breast cancer protein, ABCG2) human colorectal cells (COLO 205 COLO 320, which overexpress active ABCB1) was mainly studied this work under influence a novel synthetic acridine-based chalcone, 1C. While dropped just at 24 h, compound 1C selectively suppressed cell growth greatly lowered ABCB1 levels 320 24, 48, 72 h. It also reduced ABCC1 after 48 Molecular docking ATPase tests show that probably acts as an allosteric modulator ABCB1. galectin-1 (GAL1) Functional on revealed ABCC1/2 be major contributors both. Overall, transiently GAL1 while affecting important functional transporters, mostly lesser extent cells. 320's absence points possible yet unknown interaction between

Language: Английский

Citations

0
Nanomedicine-Based Treatments for Rare and Aggressive Ocular Cancers: Advances in Drug Delivery DOI
Devesh U. Kapoor,

Geeta Patel,

Bhupendra G. Prajapati

et al.

Current Treatment Options in Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: May 22, 2025

Language: Английский

Citations

0
Advancing the potential of nanoparticles for cancer detection and precision therapeutics DOI

Muhammad Naeem Kiani,

Hamza Khaliq,

Muhammad Abubakar

et al.

Medical Oncology, Journal Year: 2025, Volume and Issue: 42(7)

Published: June 4, 2025

Language: Английский

Citations

0